Diabetes Health
Understanding Soliqua 100/33™and Xultophy 100/3.6™: Once-Daily Injectables
Learning about: Soliqua 100/33™ and Xultophy 100/3.6™: the new once-daily injectable GLP-1 receptor agonist/basal insulin combination pens Soliqua 100/33 and Xultophy 100/3.6 are two new injectable combination products approved by the U.S. Food and Drug Administration (FDA) in November of 2016. They are used for the treatment of type 2 diabetes (T2DM) in adults who are not well-controlled on metformin or oral medications and either a basal (long-acting) insulin or a glucagon-like peptide 1 receptor...
Learning About Diabulimia
Learning About Diabulimia Most people are familiar with eating disorders such as anorexia, bulimia and binge eating disorder, but few are familiar with an eating disorder that is unique to patients with type 1 diabetes (T1DM). ED-DMT1, or what the media has dubbed “diabulimia,” is an eating disorder where patients with T1DM will purposely stop taking or significantly reduce their insulin doses to lose weight. Without enough insulin,patients with T1DM will lose calories through the...
Understanding The Story Behind Type 1.5 Diabetes
The Story Behind Type 1.5 Diabetes Type 1 and type 2 diabetes are the most well-known forms of diabetes. However, about 10% of people with diabetes have type 1.5 diabetes. Type 1.5 diabetes is also sometimes called LADA which stands for latent autoimmune diabetes in adults. Type 1 diabetes (T1DM)usually occurs during childhood but can occur later in life. It is known as an autoimmune disorder. Autoimmune disorders occur when the body uses proteins to...
1 2 3 4 >

Global Translator

Featured Recent Comments